The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

Wed, 30th Sep 2020 12:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

City Pub Group PLC - London-based pub owner and operator - Results in 26 weeks to June 28 hit by Covid-19 lockdown. Revenue slumps 55% to GBP12.1 million from GBP27.1 million in the year prior. Swings to pretax loss of GBP4.2 million from GBP946,000 profit. Says revenue since reopening at around 80% of previous levels.

----------

Time Out Group PLC - London-based media and events firm - Posts widened pretax loss of GBP18.0 million in six months ended June, from GBP12.0 million loss. Revenue during first half falls 24% to GBP20.3 million from GBP26.9 million. Notes its market locations were closed on March 16 and company added its media arm faced delays to advertising spend.

----------

Pittards PLC - leather goods manufacturer - Swings to pretax loss of GBP2.3 million in six months to June 30, from GBP224,000 profit a year earlier. Revenue down 45% year-on-year to GBP6.6 million from GBP12.1 million.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - InnovaDerma's revenue in year ended June 30 climbed 3.2% to GBP13.3 million from GBP12.9 million. Swings to pretax loss of GBP376,994 from GBP1.4 million. Marketing expenses rise 15% to GBP4.2 million, wages & salary costs climb 21% to GBP1.8 million and administrative expenses up 15% to GBP1.8 million.

----------

Polarean Imaging PLC - medical imaging products developer - Pretax loss in six months to June 30 narrows to USD3.2 million from USD3.4 million in year prior. Revenue down 18% to USD327,896 from USD399,639. Posts USD267,155 in finance income, up sharply from USD274.

----------

Tiziana Life Sciences PLC - London-headquartered biotechnology company - Posts no revenue in six months ended June 30, unchanged year-on-year. Pretax loss stretches to GBP3.9 million from GBP3.7 million in year prior. Operating expenses up 48% to GBP3.2 million from GBP2.1 million.

----------

Northbridge Industrial Services PLC - Burton-based industrial services firm - Sees revenue fall 4.5% year-on-year to GBP16.0 million in six months ended June, from GBP16.8 million. Swings to pretax loss of GBP7.7 million from GBP22,000 profit as Northbridge books GBP7.8 million in exceptional impairments.

----------

Andrews Sykes Group PLC - Wolverhampton-based heating and cooling rental company - Revenue in six months to June down 4.3% to GBP33.5 million from GBP35.0 million. Pretax profit climbs 7.0% to GBP7.2 million from GBP6.8 million. Keeps ordinary interim dividend at 11.90 pence per share but proposes special payout of 23.70p.

----------

1Spatial PLC - Cambridge-based location master data management software provider - Revenue in first half ended July 31 inches up 8.0% to GBP11.7 million from GBP10.9 million but pretax loss widens to GBP862,000 from GBP666,000. Administrative expenses up 7.8% year-on-year to GBP6.9 million.

----------

Yu Group PLC - supplier of gas, electricity and water to the UK business sector - Revenue in first half ended June 30 down 19% to GBP45.9 million from GBP56.6 million. Despite year-on-year revenue fall, pretax loss narrows to GBP2.1 million from GBP3.3 million. Total operating costs down 6.9% to GBP4.7 million.

----------

Bluejay Mining PLC - exploration and development resource company with projects in Greenland and Finland - Pretax loss in six months to June 30 widens to GBP1.2 million from GBP203,059 a year earlier. Posts no revenue, compared to GBP1,048 a year earlier. Administrative expenses up 22% annually to GBP1.2 million.

----------

Lansdowne Oil & Gas PLC - North Celtic Sea-focused oil and gas explorer - Reports no revenue in six months to June 30, as in prior year. Pretax loss widens to GBP195,000 from GBP98,000. Administration expenses more than double to GBP163,000 from GBP71,000.

----------

Panther Metals PLC - mineral exploration company focused on Canada and Australia - Posts no revenue in six months to June 30, like in year prior. Pretax loss stretches year-on-year to GBP388,126 from GBP91,458. Posts share-based payment charge of GBP135,806, swinging from credit of GBP42,814 in year prior.

----------

Ferro-Alloy Resources Ltd - vanadium mining and processing company operating in Kazakhstan - Revenue in six months to June 30 flat at USD1.1 million but pretax loss widens to USD1.7 million from USD1.3 million. Sales costs up 44% year-on-year to USD1.9 million.

----------

Volga Gas PLC - Russia-focused gas producer - Revenue in six months to June 30 shrinks 49% annually to USD13.4 million from USD26.3 million and pretax loss widens to USD7.9 million from USD3.0 million. Total output averaged 3,593 barrels of oil equivalent per day, down 36% year-on-year.

----------

Distribution Finance Capital Holdings PLC - Manchester-based capital provider to dealers and manufacturers - Revenue in six months to June 30 up 37% annually to GBP7.4 million from GBP5.4 million. Pretax loss narrows slightly to USD7.2 million from USD7.3 million. Loans and advances to customers down 2.6% to GBP163.7 million from GBP168.0 million in year prior. Also notes UK's Prudential Regulation Authority confirming Distribution Finance Capital Ltd unit authorised as a bank.

----------

Symphony International Holdings Ltd - Hong Kong-based investor - Net asset value per share at June 30 falls 43% year-on-year to USD0.62, down 37% from USD0.98 in December year end. Quarter-on-quarter, first half NAV per share rises from USD0.6043 in March, Symphony notes, amid 20% share price surge in Minor International Pcl. Symphony adds it leads jewellery firm's Melorra's USD12.5 million funding round.

----------

Manchester & London Investment Trust PLC - technology-focused growth-stock investor - Net asset value per share at July 31 year end down 10% to 625.23 pence, from 568.66p a year earlier. Posts NAV total return of 13%, beating MSCI UK Investable Market Index benchmark which lost 20%. Manchester & London holds payout at 14.00p.

----------

BMO Commercial Property Trust Ltd - London-based investment company - EPRA Net asset value per share at June 30, end of first half, down 7.8% to 120.7p from 131.0p at the end of December. Posts total return of negative 6.7%, outperformed by MSCI UK Quarterly Property Index which lost just 3.1% but fares better than FTSE All-Share Index which shed 18%. Halves dividend to 1.5p from 3.0p.

----------

Drumz PLC - investment company focused on software sector - Pretax loss in six months to June 30 widens year-on-year to GBP450,000 from GBP172,000. Like in prior year, Drumz posts no revenue. "This has been a productive period for your new board, with the introduction of the new investment policy, finalisation of the placing and completion of the company's first technology Investment," Drumz said.

----------

Metal Tiger - natural resources focused investor - Net asset value per share at June 30, end of first half, falls 13% to 15.1 pence from 17.4p at the end of December.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
4 Dec 2019 15:38

Tiziana initiates study of 'Foralumab' in coated capsule form

(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.

Read more
4 Dec 2019 11:52

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Read more
20 Nov 2019 13:02

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Read more
1 Nov 2019 17:31

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Read more
30 Sep 2019 10:27

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Read more
16 Sep 2019 13:03

Tiziana Life Sciences Gets New Foralumab Formulation US Trial Approval

(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in

Read more
10 Sep 2019 14:34

Tiziana Life Sciences Announces Positive Data From Foralumab Trial

(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a

Read more
4 Sep 2019 11:04

Encouraging Data From Tiziana Life Sciences Milciclib Cancer Study

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in

Read more
22 Jul 2019 09:54

Tiziana Reports No Drug-Related Deaths In Milciclib Liver Cancer trial

(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6

Read more
1 Jul 2019 10:49

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith,

Read more
1 Jul 2019 10:20

Tiziana Notes Positive Study Of Drug Similar To Foralumab In Diabetes

(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company

Read more
1 May 2019 10:08

FDA asks Tiziana for more information on next 'foralumab' trial

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.

Read more
24 Apr 2019 12:20

Most Patients Stick With Milciclib In Tiziana Life Sciences Study

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were -

Read more
4 Apr 2019 10:58

Tiziana Life Sciences Annual Loss Narrows On Marginally Reduced Costs

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted

Read more
20 Mar 2019 13:01

Tiziana Life Sciences Submits Application For Foralumab Trial In US

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it has submitted an application in the US to begin a phase one trial of its autoimmune and inflammatory disease drug new drug a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.